[Correspondence] Anti-BCMA CAR-T for the treatment of IgG4-related disease: clinical assessment and single-cell transcriptomic analysis

IgG4-related disease is an autoimmune disease entity with high relapse rate during and after glucocorticoid tapering, in which B cells and their deriving antibody-secreting cells exert important pathogenic effects.1 Despite several attempts of conventional immunosuppressants and B cell-targeting biologics to help reduce the risk of disease flares, there are still a number of individuals with disease relapse even within the first 6 months after treatment initiation.2,3 The successful application of chimeric antigen receptor (CAR)-T-cell therapy in treating several autoimmune diseases in those who have completely stopped immunosuppressant and glucocorticoid use implies its potential in managing IgG4-related disease.